Loading...
Market
Milestone achievements by EyeBio leading to additional payments by end of 2025?
5
Resolution / Starting Odds
No milestones achieved • 33%
Only first milestone achieved • 33%
All milestones achieved • 33%
Official Merck & Co. announcements or financial filings
Story
Merck to Acquire EyeBio for Up to $3 Billion with $1.3 Billion Upfront
May 29, 2024, 11:07 AM
Merck & Co. has announced a definitive agreement to acquire EyeBio, an ophthalmology-focused biotechnology company, for up to $3 billion. The deal includes an upfront payment of $1.3 billion, with an additional $1.7 billion contingent on achieving certain milestones. EyeBio, which is backed by Kate Bingham, is developing treatments for common eye diseases, including the Restoret drug for retinal diseases, and is set to enter late-stage clinical testing in the coming months. The acquisition brings a lead program ready for pivotal testing in diabetic macular edema. This move is part of Merck's strategy to expand its pipeline and presence in the ophthalmology market.
View original story
Similar markets
Full $1.7 billion paid • 33%
Partial milestone payments made • 33%
No milestone payments made • 34%
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
High efficacy • 33%
Moderate efficacy • 33%
Low efficacy • 34%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Phase III trial in the US • 25%
Approval in China • 25%
Approval in the EU • 25%
Partnership with another pharmaceutical company • 25%
FDA approval for another drug • 33%
Major partnership announcement • 33%
No major milestone • 33%
New drug candidate • 33%
FDA approval • 33%
New partnership • 33%
Significantly positive • 33%
Neutral • 33%
Negative • 34%